New date set for hearing of the Kenya Anti-Counterfeit court case

10 July 2011

Hearings of the constitutional case challenging the implementation of the Kenya Anti-Counterfeit Act, which was proposed in 2008 and enacted in mid-2010, has been adjourned to September 26, 2011. In Kenya, it is estimated that around 30% of drugs on the market are fakes.

This follows communication from the Attorney General office that the officer handling the case a Mr Bosire has since left the AG’s office. The AG’s office consequently asked for time to file their submission, reports Health Action International - Africa. Justice Musinga gave the AG’s office 14 days to file their submissions. The case is: JR.MISC.409/09 Patricia Asero Achieng and two others vs The Hon Attorney General was filed on July 8, 2009.

The petitioners had challenged the Kenya Anti-Counterfeit Act on the basis that it violates the right to health. The petitioners, three people living with HIV, argue that the law confuses generic medicines with counterfeits which hence threaten access to generic medicines which account for about 90% of drugs used in Kenya.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics